ScienceGlutamine transporter SLC1A5 identified as a metabolic barrier to antitumor immunity
Science reports that a Science Immunology study connects tumor metabolism to innate immune activation within tumors through SLC1A5—a finding that could inform new cancer immunotherapy.
TLDR
Science reports that a Science Immunology study used in vivo CRISPR screens to identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity. Science says the transporter couples tumor metabolism to innate immune activation within tumors, which could inform new cancer immunotherapy.
Glutamine transporter SLC1A5 identified as a metabolic barrier to antitumor immunity
Science reports that a Science Immunology study connects tumor metabolism to innate immune activation within tumors through SLC1A5—a finding that could inform new cancer immunotherapy.
TLDR
Science reports that a Science Immunology study used in vivo CRISPR screens to identify the glutamine transporter SLC1A5 as a metabolic barrier to antitumor immunity. Science says the transporter couples tumor metabolism to innate immune activation within tumors, which could inform new cancer immunotherapy.
